New Zealand markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
808.59+7.45 (+0.93%)
At close: 04:00PM EST
808.59 0.00 (0.00%)
After hours: 04:51PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 88.09B
Enterprise value 80.88B
Trailing P/E 23.06
Forward P/E 18.80
PEG ratio (5-yr expected) 1.74
Price/sales (ttm)7.03
Price/book (mrq)3.54
Enterprise value/revenue 6.18
Enterprise value/EBITDA 16.65

Trading information

Stock price history

Beta (5Y monthly) 0.12
52-week change 36.22%
S&P500 52-week change 311.63%
52-week high 3853.97
52-week low 3668.00
50-day moving average 3813.45
200-day moving average 3783.75

Share statistics

Avg vol (3-month) 3435.24k
Avg vol (10-day) 3392.1k
Shares outstanding 5107.13M
Implied shares outstanding 6108.95M
Float 8101.75M
% held by insiders 12.54%
% held by institutions 189.45%
Shares short (14 Nov 2023) 41.4M
Short ratio (14 Nov 2023) 42.74
Short % of float (14 Nov 2023) 41.53%
Short % of shares outstanding (14 Nov 2023) 41.28%
Shares short (prior month 12 Oct 2023) 41.37M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 30.47%
Operating margin (ttm)36.01%

Management effectiveness

Return on assets (ttm)9.21%
Return on equity (ttm)17.22%

Income statement

Revenue (ttm)13.1B
Revenue per share (ttm)122.63
Quarterly revenue growth (yoy)14.50%
Gross profit (ttm)7.02B
Net income avi to common (ttm)3.99B
Diluted EPS (ttm)35.09
Quarterly earnings growth (yoy)-23.40%

Balance sheet

Total cash (mrq)9.91B
Total cash per share (mrq)93.22
Total debt (mrq)2.7B
Total debt/equity (mrq)10.85%
Current ratio (mrq)5.18
Book value per share (mrq)234.46

Cash flow statement

Operating cash flow (ttm)5.22B
Levered free cash flow (ttm)3.53B